These groupings included (1) high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangement (R); (2) terminal-deoxynucleotidyl-transferase (TdT)-positive B-cell leukemia/lymphoma with or without “double/triple hit” genetics, (3) high-grade B-cell lymphomas, not otherwise specified (nos); (4) large B-cell lymphomas with IRF4-R; (5) Burkitt lymphoma; (6) high-grade/large B-cell lymphoma with 11q aberrations (HG/LBCL-11q) (formerly Burkitt-like lymphomas with 11q abnormalities (BLL 11q)); and (7) CCND1-R lymphomas, usually pleomorphic/blastoid mantle cell lymphoma. This evidence concerns the gene IRF4 and B-cell non-Hodgkin lymphoma.